Background. Phase II and III clinical studies were conducted to evaluate immunogenicity and safety of a novel DTaP-IPV vaccine consisting of Sabin inactivated poliovirus vaccine (sIPV) and diphtheria-tetanus-acellular pertussis vaccine (DTaP).
Since the World Health Organization (WHO) launched the global polio eradication program in 1988, the number of patients with polio caused by wild-type polioviruses worldwide has steadily decreased from a 1988 estimate of approximately 350 000 cases to 67 cases on 5 June 2012 [1] . The oral polio vaccine (OPV) has played a leading role in the program as not only is it very effective and safe but it also has several important advantages, including low cost, ease of administration, and induction of superior mucosal immunity, compared to inactivated polio vaccine (IPV). In poliofree areas, however, concerns have been raised regarding 2 negative aspects of OPV as a live vaccine: One issue is a risk of causing vaccine-associated paralytic poliomyelitis (VAPP) in OPV vaccinees and those in contact with them, although this occurred very infrequently [2] . The other issue is a risk of polio epidemics caused by vaccine-derived polioviruses (VDPVs), which have highly neurovirulent and transmissible properties [3] . As long as OPV is in use, it will be impossible to avoid the occurrence of VAPP and polio caused by VDPVs. Therefore, many countries in which polio has been eradicated have been shifting from OPV to IPV.
In addition to conventional IPV produced using virulent polioviruses (cIPV), a novel IPV produced using nonvirulent poliovirus seed strains, such as the attenuated Sabin strains, is now under investigation. However, with a view to eradicating wild-type polioviruses, regulations have been placed on manufacturing of bulk cIPV from virulent poliovirus strains at new manufacturing sites [4] . On the other hand, manufacturing of an IPV using attenuated Sabin strains (sIPV) is not regulated because it is made from attenuated Sabin strains. Moreover, the use of attenuated Sabin strains not only provides additional safety during vaccine production, but also reduces the risk of recurrent polio epidemics in the unlikely event of an unintentional or intentional release into the human population or environment. Therefore, manufacturing of sIPV is also encouraged by the WHO in consideration of social safety and IPV supply post polio eradication [5, 6] .
The first Phase I clinical study using an sIPV was carried out in the United States starting in 1985 to evaluate its safety and immunogenicity [7] . Since then, many institutes have been continuing the development of sIPV to further optimize doses through preclinical and clinical studies [8] [9] [10] .
The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) initiated development of a diphtheria-tetanus-acellular pertussis (DTaP) vaccine that contains a domestically produced sIPV (DTaP-sIPV). The optimum dose of the sIPV in DTaPsIPV was determined in a Phase II clinical study, and the safety and immunogenicity of DTaP-sIPV manufactured at the optimum dose of the sIPV were evaluated in a Phase III clinical study. This is the first report on the immunogenicity and safety of the sIPV in the Phase III study.
MATERIALS AND METHODS

Vaccines
Type 1, type 2, and type 3 sIPV bulk stocks manufactured by Japan Poliomyelitis Research Institute were purchased to manufacture DTaP-sIPV [10] . The following Sabin strains were used to manufacture the sIPV bulks: LSc, 2ab strain for type 1; P712, Ch, 2ab strain for type 2; and Leon, 12a 1 b strain for type 3.
Given a previous report that the immunogenicity of sIPV differs from that of cIPV, it was necessary to select the optimum dose of sIPV [11] . The National Institute of Infectious Diseases, Japan, played a central role to determine the required D-antigen units (DU) content of sIPV that would be equivalent to the WHO reference IPV (91/574) or cIPV derived from virulent polioviruses (type 1 : type 2 : type 3 = 40 DU : 8 DU : 32 DU) in terms of immunogenicity using rats, and concluded that the relevant DU of sIPV is 3, 100, and 100 DU for types 1, 2, and 3, respectively [10] . Guoyang Liao et al [9] conducted a Phase II clinical study of sIPV in China, and reported that the appropriate concentrations of sIPV were 15 DU, 32 DU, and 45 DU for types 1, 2, and 3, respectively. However, regarding the methods of testing for D-antigen content, the antibody and standards that Guoyang Liao et al used in their study differed from those used in the present study. Therefore, we could not compare the antigen contents. As the DTaP components, antigens (diphtheria toxoid, tetanus toxoid, pertussis toxoid [PT]) and filamentous hemagglutinin (FHA) manufactured by Kaketsuken were used [12] [13] [14] [15] [16] .
The final bulk of DTaP-sIPV was prepared by mixing a trivalent sIPV with the licensed DTaP final bulk. Syringes were used as single-dose containers of the final product. In addition to Formulation H, a DTaP-sIPV containing the same amount as the sIPV (type 1 : type 2 : type 3 = 3 DU : 100 DU : 100 DU), Formulations M and L, containing half and one-fourth of the amount in the sIPV, respectively, were prepared to determine the optimum dose of sIPV in DTaP-sIPV in the Phase II study. These formulations differed only in the amount of sIPV. In the Phase III study, the DTaP vaccine (manufactured by Kaketsuken), the OPV vaccine ( Japan Poliomyelitis Research Institute), and an OPV placebo ( Japan Poliomyelitis Research Institute), excluding the active ingredient (Sabin viruses) from the OPV vaccine, were used as control drugs. The DTaP vaccine contained 4 U ( pertussis protective unit) or more of Bordetella pertussis protective antigen, 16.7 limit of flocculation (Lf ) or less of diphtheria toxoid, and 6.7 Lf or less of tetanus toxoid per dose. The OPV contained 6.0, 5.0, and 5.5 log 10 50% cell culture infectious doses for Sabin types 1, 2, and 3, respectively.
Study Design
Phase II Study
The immunogenicity and safety of Formulations H, M, and L were evaluated in 104 healthy infants (age range, 3-89 months) who were recruited between 12 May and 20 June 2009. This was a multicenter, randomized, double-blind, parallel-group study. After informed consent was obtained from parents, eligible participants were randomly assigned to 3 groups (Group H, Group M, and Group L), which received Formulation H, M, or L, respectively. Formulation H, M, or L was subcutaneously administered at a dose of 0.5 mL four times as follows: a series of 3 doses given at intervals of 3-8 weeks for primary immunization, and 1 dose for booster immunization 6-18 months after the third vaccination.
Phase III Study
The immunogenicity and safety of DTaP-sIPV (Formulation M) was evaluated in 342 healthy infants (age range, 3-89 months) who were recruited between 9 March and 30 June 2010, using DTaP plus OPV as a control. This was a multicenter, randomized, double-blind, parallel-group study. After informed consent was obtained, eligible participants were randomly assigned to 2 groups, Group M and the Control group, which received either Formulation M and OPV placebo, or DTaP and OPV, respectively. Formulation M or DTaP was subcutaneously administered at a dose of 0.5 mL four times as follows: a series of 3 doses given at intervals of 3-8 weeks for primary immunization, and 1 dose for booster immunization 6-18 months after the third vaccination. OPV placebo or OPV at a dose of 0.05 mL was orally administered twice at an interval of at least 6 weeks during the period from completion of blood collection for primary immunization with Formulation M or DTaP to 35 days before booster immunization.
In the Phase II and Phase III studies, blood was collected before immunization, 4-6 weeks after primary immunization, before booster immunization, and 4-6 weeks after booster immunization to determine the antibody titers against attenuated poliovirus strains (Sabin 1, 2, and 3 strains), PT, FHA, diphtheria toxin, and tetanus toxin. The neutralizing antibody titers against virulent poliovirus strains were determined only in the Phase II study. Participants were monitored for safety by means of a health diary for 27 days after immunization. Those who received OPV placebo or OPV in the Phase III study were monitored for safety by means of a health diary for 34 days after immunization. For severity classification, the criteria were defined in Grades 1 to 4, with Grade 4 being the most severe grade. These clinical studies were conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, Good Clinical Practice, and relevant regulatory laws.
Serological Methods
The neutralizing antibody titers against polioviruses were determined by neutralization test [17] . Challenge viruses were Sabin strains (types 1, 2, and 3) and virulent poliovirus strains (type 1: Mahoney strain; type 2: MEF-1 strain; type 3: Saukett strain). The protective level of neutralizing antibody titer against Sabin strains and virulent poliovirus strains was thought to be 1:8 or more [18] . The antibody titers against PT and FHA were determined using a Wako reagent kit for anti-Bordetella pertussis antibody titers. The protective level of antibody titers against both PT and FHA was 10 enzyme-linked immunosorbent assay (ELISA) units (EU)/mL [19] . The neutralizing antibody titer against diphtheria toxin was determined by neutralization test using Vero cells as indicator cells. The protective level of antibody titer against diphtheria toxin was 0.1 international units (IU)/mL [20] . The antibody titer against tetanus toxin was determined using a KPA kit (manufactured by Kaketsuken). In this system, the tetanus antibody titer is measured based on indirect agglutination using sensitized particles (artificial synthetic particles bound to tetanus toxoid). The protective level of antibody titer against tetanus toxin was 0.01 IU/mL [21] .
Statistics
Phase II Study For each group, the seropositive rate, the geometric mean antibody titer (GMT), and their 2-sided 95% confidence intervals (CIs) after primary and booster immunizations were calculated for all active components. In terms of sample size, from the results of an immunogenicity examination of the primary immunization conducted in the previous clinical trial, as well as immunogenicity tests in Macaca fascicularis, it was thought possible to confirm the dose response (α = .025 [1-tailed test]; β = .20, power of 0.80, contrast method) with 20 participants or less per group. However, considering the inevitable attrition of study participants, we required 30 participants per group.
Phase III Study
The primary endpoint in this study was the seropositive rates of Group M, which were to be higher than 90% for Sabin types 1, 2, and 3 after primary immunization. The secondary endpoint was that the seropositive rates for all components of DTaP after primary immunization in Group M were not to be inferior to those in the Control group. To verify that the seropositive rates (p 1 ) for neutralizing antibodies against Sabin types 1, 2, and 3 in Group M were higher than the statistical tolerance limit ( p 0 ) (90%) for the analysis of the primary endpoint, the following were tested by 1-sample binomial test with a 1-sided significance level of 2.5%: the null hypothesis that the respective seropositive rates ( p 1 ) were equal to or lower than the statistical tolerance limit ( p 0 ) (H 0 ; p 0 ≥ p 1 ); and an alternative hypothesis that the respective seropositive rates ( p 1 ) were higher than the statistical tolerance limit ( p 0 ) (H 1 ; p 0 < p 1 ). To verify that the seropositive rate against PT, FHA, diphtheria toxin, or tetanus toxin in Group M was not inferior to the Control group by more than 10% for the analysis of the secondary endpoint (clinically acceptable maximum difference [s 0 ]), a 1-sided Farrington-Manning test was used with a significance level of 2.5%. The full-analysis set (FAS) was used to represent the immunogenicity population for the primary endpoint, because this analysis was intended to verify the superiority. The perprotocol set (PPS) was used to represent the immunogenicity population for the secondary endpoint, because this analysis was intended to verify the noninferiority. In terms of sample size, an accurate sample size of 180 participants in Group M was needed to verify that the seropositive rates ( p 1 ) for neutralizing antibodies against Sabin types 1, 2, and 3 of the primary endpoint were higher than the statistical tolerance limit ( p 0 ) (90%), (α = .025 [1-tailed test]; β = 0.115, power of 0.96 3 , expectation value = 97%). Because of an inevitable attrition of study participants, we required 210 patients in Group M. Eligible participants were randomly assigned in a 2:1 ratio to Group M and the Control group, respectively. Even for calculations regarding the secondary endpoint, the number of participants was sufficient.
RESULTS
Phase II Clinical Study
All 104 participants were included in the safety population, and 102 participants (Group H: 32; Group M: 38; Group L: 32) who received the booster immunization were included in the FAS immunogenicity population (2 participants did not receive the booster immunization: 1 in Group H who withdrew consent, and 1 in Group L who moved elsewhere).
The seropositive rate was 100% for all poliovirus strains in all groups, except for virulent type 1 after primary immunization. There was no clear dose response effect among the Sabin strain groups. After primary immunization, the seropositive rates against the virulent type 1 in Groups H, M, and L were 90.9% (30/33 participants), 97.4% (37/38), and 97.0% (32/33), respectively. However, after the booster immunization, the seropositive rate was 100% for all virulent types as well as for all Sabin strains in all groups. The GMTs (log 2 ) against polioviruses after primary and booster immunizations are shown in Table 1 . After primary and booster immunizations, no clear dose response was observed in the neutralizing antibody titers.
As for adverse reactions, the incidence of erythema at the injection site was 87.9% (29/ 8-66.5) in Groups H, M, and L, respectively. The incidence of adverse reactions was higher in Group H compared with Groups M and L; however, there were no statistically significant differences among the 3 groups. Considering the GMT (Table 1 ) and adverse reactions, we selected Formulation M containing type 1 : type 2 : type 3 = 1.5 DU : 50 DU : 50 DU of sIPV in the DTaP-sIPV as the optimum dose.
Phase III Clinical Study
In this study, the immunogenicity and safety of Formulation M, selected as the optimum dose in the previous Phase II study, were evaluated. Of 342 participants enrolled in the study, 221 and 121 participants were randomly assigned to Group M and the Control group, respectively (Figure 1) . A total of 337 participants completed this study. All participants were included in the safety population. One participant in the Control group withdrew from this study after the first immunization because of relocation, with no postimmunization. Therefore, this participant was excluded from the FAS immunogenicity population. There were 336 participants in the PPS immunogenicity population, after the exclusion of protocol deviations. The baseline attributes of participants are shown in Table 2 . In both groups, the preimmunization seropositive rate was high for tetanus and low for poliovirus type 3. No statistically significant differences were observed in the baseline factors between the 2 groups.
Immunogenicity
Primary Immunization
The seropositive rates and GMTs after primary immunization are shown in Table 3 . The seropositive rate was 100.0% for Sabin types 1, 2, and 3 after primary immunization. The null hypothesis (seropositive rate ≤90%) was rejected by binomial test (P < .001), verifying that the seropositive rates of Group M were higher than 90% for Sabin types 1, 2, and 3 after primary immunization, which met the primary endpoint.
In addition, results of the Farrington-Manning test verified that Group M was not inferior to the Control group in terms of 
Booster Immunization
The seropositive rates and GMTs after booster immunization are shown in Table 4 . In Group M, the seropositive rate was 100.0% for all neutralizing antibodies against Sabin types 1, 2, and 3 after booster immunization. After booster immunization, the GMTs (log 2 ) against Sabin types 1, 2, and 3 were higher in Group M than in the Control group, and they were almost similar among these 3 types in Group M, whereas the GMT against Sabin type 3 tended to be lower in the control OPV group. The seropositive rate was 100.0% for all components of DTaP in both groups. In addition, the GMTs against each component of DTaP further increased after primary immunization. The GMTs against each component of DTaP were almost the same in Group M and the Control group, showing that the addition of sIPV did not affect the immunogenicity of DTaP in Formulation M.
Safety
Adverse reactions with an incidence of ≥5% in this study are listed in Table 5 . The most common adverse reaction was Figure 1 . Flow of Phase III study. Abbreviations: DTaP, diphtheria-tetanus-acellular pertussis; FAS, full-analysis set; OPV, oral polio vaccine; PPS, per-protocol set.
injection-site erythema, but most participants were <Grade 3 (long diameter <5 cm). The most common systemic adverse reaction was pyrexia, but most participants were <Grade 3 (<39.0°C) in both groups. There were no statistically significant differences in the incidence of Grade 3 or more severe pyrexia between the 2 groups. Serious adverse reactions occurred in 2 participants. One participant in Group M was hospitalized due to convulsions that occurred 20 days after the first immunization with Formulation M. The patient recovered well 4 days after hospitalization. The doctor who took care of this patient commented that a relationship between this case and Formulation M was probably very low, however, it could not be completely denied. The other participant, in the Control group, was hospitalized due to pneumonia that occurred 22 days after the third immunization with DTaP. The patient recovered well 4 days after hospitalization. The doctor commented that a relationship could not be completely denied. Neither participant was withdrawn from the study due to the adverse reaction. Based on these results, it is considered that all adverse reactions were clinically acceptable.
DISCUSSION
The Phase II and Phase III clinical studies revealed that the DTaP-sIPV (Formulation M) induced a 100% seropositive rate not only for the 3 types of Sabin strains, but also for the virulent poliovirus strains (type 1: Mahoney strain, type 2: MEF-1 strain, type 3: Saukett strain) after the booster immunization. In the manufacturing of DTaP-sIPV, the addition of sIPV did not affect the immunogenicity of any DTaP component. Formulation M was well tolerated. Based on the immunogenicity and safety data obtained in these clinical studies, this DTaP-sIPV was approved and licensed for use in Japan in July 2012 prior to its worldwide approval.
DTaP-sIPV has been developed with 3 objectives. The first objective is to prevent VAPP while maintaining a high immunity against polio. Theoretically, VAPP will not occur if the OPV is replaced with an sIPV. In addition, the high immunization rate of sIPV is expected to be maintained with DTaP-sIPV by combining an sIPV with DTaP.
The second objective is to prevent paralytic poliomyelitis caused by VDPVs. The spread of VDPVs has been suppressed by enhancing the routine immunization with an OPV [3] . In this study, the titers of neutralizing antibodies against polioviruses induced by the DTaP-sIPV were higher than those induced by OPV. Simply comparing the neutralizing antibody titers may not be sufficient to evaluate the comparative strength of sIPV and OPV against poliovirus, because sIPV and OPV may have different mechanisms for protection against polio. However, it has been shown that neutralizing antibodies play a major role in the protection, considering the efficacy of passive immunization of gamma globulin and active immunization of cIPV to control wild-type polioviruses [22] [23] [24] [25] . Therefore, the DTaP-sIPV may also be effective against VDPVs. In fact, transgenic mice immunized with an sIPV were protected against VDPV [26] .
The third objective is to prevent paralytic poliomyelitis caused by wild-type viruses. While the eradication of polio caused by wild-type viruses is close to completion, the possibility of polio import cannot be ruled out, given a recent outbreak in China [27] . Therefore, it is very important to understand whether immunity induced by sIPV can prevent polio caused by wild-type polioviruses. The efficacy of DTaP-sIPV should have been evaluated in an efficacy study, but it was impossible to conduct such a study in Japan where polio has already been eradicated. Therefore, in this study we used the neutralizing antibody titer as a surrogate marker.
In the Phase II clinical study, the seropositive rate was 100% for the virulent poliovirus types 1, 2, and 3 after the booster immunization with Formulation M. The neutralizing antibody titer against virulent poliovirus strains was similar to that against corresponding Sabin types 2 and 3, but the titer against the virulent poliovirus type 1 tended to be lower than that against corresponding Sabin type 1, although being much higher than the protective level. Subsequently, the neutralizing antibody concentrations (IU/mL) were calculated using the international standard serum provided by the National Institute for Biological Standards and Control for comparison with the previously reported results of clinical studies of cIPV, as shown in Table 6 [28, 29] . The concentration of neutralizing antibody against virulent type 1 induced by Formulation M after the Abbreviations: CI, confidence interval; cIPV, conventional IPV produced using virulent polioviruses; DTaP, diphtheria-tetanus-acellular pertussis; IPV, inactivated polio vaccine; IU, international units; OPV, oral polio vaccine; sIPV, IPV using attenuated Sabin strains. a The neutralizing antibody titers (log 2 ) were converted into the neutralizing antibody concentrations (IU/mL) using international standard serum provided by the National Institute for Biological Standards and Control. b DTaP-sIPV and cIPV were administered in 3 doses and 2 doses, respectively, for primary immunization.
c Data were cited from reference No. 28. primary and booster immunizations was comparable to that after the primary and booster immunizations with a cIPV, indicating that Formulation M is expected to prevent polio caused by wild-type polioviruses as effectively as the cIPV with an established efficacy. In a similar analysis for virulent types 2 and 3, the antibody concentration after the primary and booster immunizations with Formulation M was equal to or higher than that with cIPV, strongly suggesting that DTaP-sIPV is also effective for wild-type polioviruses.
Notes
